Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
- PMID: 30850440
- PMCID: PMC6448453
- DOI: 10.1212/WNL.0000000000007242
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Abstract
Objective: To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS).
Methods: A consensus committee comprising 140 key members of the international ALS community (ALS researchers, clinicians, patient representatives, research funding representatives, industry, and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies; (2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical trial phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8 sections, committee members generated a draft set of guidelines based on a "background" of developing a (pre)clinical question and a "rationale" outlining the evidence and expert opinion. Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified Delphi process was used to develop draft consensus research guidelines, which were subsequently reviewed and modified based on comments from the public. Statistical experts drafted a separate document of statistical considerations (section 9).
Results: In this report, we summarize 112 guidelines and their associated backgrounds and rationales. The full list of guidelines, the statistical considerations, and a glossary of terms can be found in data available from Dryad (appendices e-3-e-5, doi.org/10.5061/dryad.32q9q5d). The authors prioritized 15 guidelines with the greatest potential to improve ALS clinical research.
Conclusion: The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to improve clinical trial design and accelerate the development of effective treatments for patients with ALS.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors.J Neurol Sci. 1995 May;129 Suppl:1-10. J Neurol Sci. 1995. PMID: 7595596 Review. No abstract available.
-
Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.J Neurol Sci. 1999 Oct 31;169(1-2):2-12. doi: 10.1016/s0022-510x(99)00209-9. J Neurol Sci. 1999. PMID: 10540001 Review.
-
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment.Neurology. 2019 Jul 9;93(2):66-71. doi: 10.1212/WNL.0000000000007695. Epub 2019 Jun 6. Neurology. 2019. PMID: 31171646 Free PMC article. Review.
-
Clinical trials in amyotrophic lateral sclerosis.Curr Opin Neurol. 2019 Oct;32(5):758-763. doi: 10.1097/WCO.0000000000000731. Curr Opin Neurol. 2019. PMID: 31335338 Review.
Cited by
-
Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia.Biomolecules. 2022 Dec 22;13(1):26. doi: 10.3390/biom13010026. Biomolecules. 2022. PMID: 36671411 Free PMC article. Review.
-
Improving clinical trial outcomes in amyotrophic lateral sclerosis.Nat Rev Neurol. 2021 Feb;17(2):104-118. doi: 10.1038/s41582-020-00434-z. Epub 2020 Dec 18. Nat Rev Neurol. 2021. PMID: 33340024 Free PMC article. Review.
-
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.Brain. 2021 Oct 22;144(9):2635-2647. doi: 10.1093/brain/awab167. Brain. 2021. PMID: 33905493 Free PMC article. Clinical Trial.
-
Optimal Therapeutic Strategy of Bone Marrow-Originated Autologous Mesenchymal Stromal/Stem Cells for ALS.Stem Cells Transl Med. 2024 Apr 15;13(4):309-316. doi: 10.1093/stcltm/szad095. Stem Cells Transl Med. 2024. PMID: 38244235 Free PMC article. Review.
-
Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis.Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8. Sci Rep. 2020. PMID: 32576912 Free PMC article.
References
-
- Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci 1999;169:2–12. - PubMed
-
- Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13:1127–1138. - PubMed
-
- Writing Group; Edaravone (MCI-186) ALS Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–512. - PubMed
-
- Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014;345:1247125. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous